Steven Valiquette
Stock Analyst at Mizuho
(3.38)
# 905
Out of 5,173 analysts
127
Total ratings
50%
Success rate
3.61%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LFMD LifeMD | Upgrades: Outperform | $6 → $8 | $3.98 | +101.01% | 3 | Mar 16, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $14 → $16 | $11.54 | +38.65% | 9 | Mar 2, 2026 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $2.08 | +44.23% | 2 | Feb 27, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $81 → $88 | $74.46 | +18.18% | 7 | Feb 25, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $25.03 | +35.84% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $25.82 | +4.57% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $206.40 | +13.86% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $877.01 | +0.91% | 5 | Feb 5, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $180.86 | +10.58% | 13 | Jan 20, 2026 | |
| SOLV Solventum | Upgrades: Outperform | $85 → $100 | $65.69 | +52.23% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $42.48 | +12.99% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $28 | $11.80 | +137.29% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $320.61 | +18.52% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $24.62 | +103.09% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $185.23 | +75.46% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.48 | +82.48% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $81.64 | +54.34% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $5.14 | -2.72% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $188.09 | -24.50% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $81.85 | -32.80% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $195.00 | -52.82% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $269.54 | +109.62% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $71.29 | +40.27% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $135.24 | +195.77% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $32.81 | +226.12% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $37.45 | -54.61% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $13.89 | -13.61% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $97.52 | -1.56% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $195.60 | -38.65% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $494.58 | -74.32% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $170.14 | +110.41% | 3 | Dec 6, 2019 |
LifeMD
Mar 16, 2026
Upgrades: Outperform
Price Target: $6 → $8
Current: $3.98
Upside: +101.01%
DENTSPLY SIRONA
Mar 2, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $11.54
Upside: +38.65%
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $2.08
Upside: +44.23%
Henry Schein
Feb 25, 2026
Maintains: Neutral
Price Target: $81 → $88
Current: $74.46
Upside: +18.18%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $25.03
Upside: +35.84%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $25.82
Upside: +4.57%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $206.40
Upside: +13.86%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $877.01
Upside: +0.91%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $180.86
Upside: +10.58%
Solventum
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $65.69
Upside: +52.23%
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $42.48
Upside: +12.99%
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $11.80
Upside: +137.29%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $320.61
Upside: +18.52%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $24.62
Upside: +103.09%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $185.23
Upside: +75.46%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $5.48
Upside: +82.48%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $81.64
Upside: +54.34%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $5.14
Upside: -2.72%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $188.09
Upside: -24.50%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $81.85
Upside: -32.80%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $195.00
Upside: -52.82%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $269.54
Upside: +109.62%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $71.29
Upside: +40.27%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $135.24
Upside: +195.77%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $32.81
Upside: +226.12%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $37.45
Upside: -54.61%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $13.89
Upside: -13.61%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $97.52
Upside: -1.56%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $195.60
Upside: -38.65%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $494.58
Upside: -74.32%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $170.14
Upside: +110.41%